It was not able to determine whether serum FSTL3 played a mediating role in it, nor to verify whether T2DM and NAFLD had an additive effect on the occurrence and development of AMI. The gene discussed is FSTL3; the disease is metabolic dysfunction-associated steatotic liver disease.